1-(2-fluoro-β-D-ribopentofuranosyl-4-carboxymethyl)uracil | 1558010-66-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-(2-fluoro-β-D-ribopentofuranosyl-4-carboxymethyl)uracil
• 英文别名: methyl (2S,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-tetrahydrofuran-2-carboxylate；methyl (2S,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxyoxolane-2-carboxylate
• CAS: 1558010-66-4
• 化学式: C₁₀H₁₁FN₂O₆
• 分子量: 274.206
• InChiKey: MGWTYMDDBMAEEE-VGRMVHKJSA-N

物化性质

• 密度：
  1.58±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  105
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  甲醇 、 (2S,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxyoxolane-2-carboxylic acid 在 硫酸 作用下， 反应 5.0h， 以28%的产率得到1-(2-fluoro-β-D-ribopentofuranosyl-4-carboxymethyl)uracil
  参考文献：
  名称：

  4′-Substituted pyrimidine nucleosides lacking 5′-hydroxyl function as potential anti-HCV agents

  摘要：

  Hepatitis C virus (HCV) infection is one of the major health problems worldwide. If left untreated, it leads to liver cirrhosis, liver cancer and death. Herein, we report synthesis and anti-HCV activity of a new class of pyrimidine nucleosides possessing a 4'-carboxymethyl (9-16, 21 and 23) or 4'-carboxamide function (17-19 and 24). Among these, 10-12 (EC50 = 33.1-42.4 mu M), 14 and 21 (EC50 = 43.4-59.5 mu M) exhibited potent activity in HCV-1a replicon cells without any toxicity to parent Huh-7 cells (CC50 = > 829-1055 mu M). The anti-HCV activities demonstrated by this unusual class of compounds were superior to that of ribavirin (EC50 = 81.9 lM). Further, the most active analog, 12, was found to interact synergistically with ribavirin to inhibit HCV RNA replication. (C) 2014 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2014.01.024

文献信息

• Substituted nucleosides, nucleotides and analogs thereof
  申请人：ALIOS BIOPHARMA, INC.

  公开号：US10307439B2

  公开（公告）日：2019-06-04

  Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Coronaviridae virus, a Togaviridae virus, a Hepeviridae virus and/or a Bunyaviridae virus infection with one or more nucleosides, nucleotides and nucleotide analogs.

  本文公开了核苷、核苷酸和核苷酸类似物、合成方法以及用一种或多种核苷、核苷酸和核苷酸类似物治疗冠状病毒科病毒、妥加病毒科病毒、肝病毒科病毒和/或布尼亚病毒科病毒感染等疾病和/或病症的方法。
• 4′-Substituted pyrimidine nucleosides lacking 5′-hydroxyl function as potential anti-HCV agents
  作者：Neeraj Shakya、Satish Vedi、Chao Liang、Fang Yang、Babita Agrawal、Rakesh Kumar

  DOI：10.1016/j.bmcl.2014.01.024

  日期：2014.3

  Hepatitis C virus (HCV) infection is one of the major health problems worldwide. If left untreated, it leads to liver cirrhosis, liver cancer and death. Herein, we report synthesis and anti-HCV activity of a new class of pyrimidine nucleosides possessing a 4'-carboxymethyl (9-16, 21 and 23) or 4'-carboxamide function (17-19 and 24). Among these, 10-12 (EC50 = 33.1-42.4 mu M), 14 and 21 (EC50 = 43.4-59.5 mu M) exhibited potent activity in HCV-1a replicon cells without any toxicity to parent Huh-7 cells (CC50 = > 829-1055 mu M). The anti-HCV activities demonstrated by this unusual class of compounds were superior to that of ribavirin (EC50 = 81.9 lM). Further, the most active analog, 12, was found to interact synergistically with ribavirin to inhibit HCV RNA replication. (C) 2014 Published by Elsevier Ltd.